NeuroTherapeutics Pharma Obtains $43,000,000 Series B Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a06ed8d4-54f0-466a-b242-9333c4495766&Preview=1 -
Date
5/20/2010 -
Company Name
NeuroTherapeutics Pharma -
Mailing Address
8420 West Bryn Mawr Avenue Chicago, IL 60631 -
Company Description
NeuroTherapeutics Pharma (NTP) is an early stage company focused on the development of therapies for CNS disorders with an initial focus on epilepsy. -
Website
http://www.ntprx.com -
Transaction Type
Venture Equity -
Transaction Amount
$43,000,000 -
Transaction Round
Series B -
Proceeds Purposes
The company’s Series B financing will advance NTP-2014 up to and through multiple proof-of-concept Phase II trials and further develop a pipeline to expand this new class of therapy. -
M&A Terms
-
Venture Investor
SR One -
Venture Investor
MPM Capital -
Venture Investor
Fidelity BioSciences -
Venture Investor
Novo A/S -
Venture Investor
Pfizer Strategic Investments Group -
Venture Investor
Thomas, McNerny & Partners
